PDPerry Devo

Perry Devo

*This is an algorithmically generated author record based on publicly available information.

Perry Devo has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Camilla Russo

    School of Science Faculty of Engineering and Science University of Greenwich Chatham Maritime Chatham Kent ME4 4TB UK

    2 shared publications
  • Charles A. I. Goodall

    School of Science Faculty of Engineering and Science University of Greenwich Chatham Maritime Chatham Kent ME4 4TB UK

    2 shared publications
  • Cyrille Kiaku

    School of Science Faculty of Engineering and Science University of Greenwich Chatham Maritime Chatham Kent ME4 4TB UK

    2 shared publications
  • Darren Lee Poole

    Molecular Modalities Capabilities, GSK Medicines Research Centre, Gunnels Wood Rd., Stevenage SG1 2NY, U.K.

    2 shared publications
  • Emmanuelle Lambert

    School of Science Faculty of Engineering and Science University of Greenwich Chatham Maritime Chatham Kent ME4 4TB UK

    2 shared publications
  • Jamie M. Walsh

    School of Science Faculty of Engineering and Science University of Greenwich Chatham Maritime Chatham Kent ME4 4TB UK

    2 shared publications

Latest Publications

  • Open Access

    Exosomes in the Diagnosis and Treatment of Renal Cell Cancer

    by Stergios Boussios, Perry Devo, Iain C. A. Goodall, Konstantinos Sirlantzis, Aruni Ghose, Sayali D. Shinde, Vasileios Papadopoulos, Elisabet Sanchez, Elie Rassy, Saak V. Ovsepian

    Renal cell carcinoma (RCC) is the most prevalent type of kidney cancer originating from renal tubular epithelial cells, with clear cell RCC comprising approximately 80% of cases. The primary treatment modalities for RCC are surgery and targeted therapy, albeit with suboptimal efficacies. Despite progress in RCC research, significant challenges persist, including advanced distant metastasis, delayed diagnosis, and drug resistance. Growing evidence suggests that extracellular vesicles (EVs) play a pivotal role in multiple aspects of RCC, including tumorigenesis, metastasis, immune evasion, and drug response. These membrane-bound vesicles are released into the extracellular environment by nearly all cell types and are capable of transferring various bioactive molecules, including RNA, DNA, proteins, and lipids, aiding intercellular communication. The molecular cargo carried by EVs renders them an attractive resource for biomarker identification, while their multifarious role in the RCC offers opportunities for diagnosis and targeted interventions, including EV-based therapies. As the most versatile type of EVs, exosomes have attracted much attention as nanocarriers of biologicals, with multi-range signaling effects. Despite the growing interest in exosomes, there is currently no widely accepted consensus on their subtypes and properties. The emerging heterogeneity of exosomes presents both methodological challenges and exciting opportunities for diagnostic and clinical interventions. This article reviews the characteristics and functions of exosomes, with a particular reference to the recent advances in their application to the diagnosis and treatment of RCC.


  • Open Access

    Ageing perspective on cognitive outcomes from ancillary reproductive hormone adjustments

    by Grace Zhang, Perry Devo, Valerie B. O'LEary, Saak V. Ovsepian


  • Open Access

    eHydrogenation: Hydrogen‐free Electrochemical Hydrogenation

    by Camilla Russo, Matthew C. Leech, Jamie M. Walsh, Joe I. Higham, Lisa Giannessi, Emmanuelle Lambert, Cyrille Kiaku, Darren L. Poole, Joseph Mason, Charles A. I. Goodall, et al.

    Hydrogenation reactions are staple transformations commonly used across scientific fields to synthesise pharmaceuticals, natural products, and various functional materials. However, the vast majority of these reactions require the use of a toxic and costly catalyst leading to unpractical, hazardous and often functionally limited conditions. Herein, we report a new, general, practical, efficient, mild and high‐yielding hydrogen‐free electrochemical method for the reduction of alkene, alkyne, nitro and azido groups. Finally, this method has been applied to deuterium labelling.


  • Open Access

    eHydrogenation: Hydrogen‐free Electrochemical Hydrogenation

    by Camilla Russo, Matthew C. Leech, Jamie M. Walsh, Joe I. Higham, Lisa Giannessi, Emmanuelle Lambert, Cyrille Kiaku, Darren L. Poole, Joseph Mason, Charles A. I. Goodall, et al.

    Hydrogenation reactions are staple transformations commonly used across scientific fields to synthesise pharmaceuticals, natural products, and various functional materials. However, the vast majority of these reactions require the use of a toxic and costly catalyst leading to unpractical, hazardous and often functionally limited conditions. Herein, we report a new, general, practical, efficient, mild and high‐yielding hydrogen‐free electrochemical method for the reduction of alkene, alkyne, nitro and azido groups. Finally, this method has been applied to deuterium labelling.